Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.

Guo T, Agaram NP, Wong GC, Hom G, D'Adamo D, Maki RG, Schwartz GK, Veach D, Clarkson BD, Singer S, DeMatteo RP, Besmer P, Antonescu CR.

Clin Cancer Res. 2007 Aug 15;13(16):4874-81.

2.

Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor.

Yuzawa S, Opatowsky Y, Zhang Z, Mandiyan V, Lax I, Schlessinger J.

Cell. 2007 Jul 27;130(2):323-34.

3.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG.

Lancet. 2006 Oct 14;368(9544):1329-38.

PMID:
17046465
4.

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ, Fletcher JA.

J Clin Oncol. 2006 Oct 10;24(29):4764-74. Epub 2006 Sep 5.

PMID:
16954519
5.

An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, Park SH, Hwang JH, Rha SY, Kweon GR, Lee SJ, Jo KW, Shong M.

J Clin Endocrinol Metab. 2006 Oct;91(10):4070-6. Epub 2006 Jul 18.

PMID:
16849418
6.

Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones.

Loughrey MB, Beshay V, Dobrovic A, Zalcberg J, Waring PM.

Histopathology. 2006 Jul;49(1):99-100. No abstract available.

PMID:
16842259
7.

Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour.

Bertucci F, Goncalves A, Monges G, Madroszyk A, Guiramand J, Moutardier V, Noguchi T, Dubreuil P, Sobol H.

Oncol Rep. 2006 Jul;16(1):97-101.

PMID:
16786129
8.

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.

Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM, Mendel DB.

Mol Cancer Ther. 2006 May;5(5):1280-9.

9.

Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.

Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schöffski P, Van Oosterom A, Marynen P, Debiec-Rychter M.

Clin Cancer Res. 2006 Apr 15;12(8):2622-7.

10.

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, Blay JY, Leyvraz S, Stul M, Casali PG, Zalcberg J, Verweij J, Van Glabbeke M, Hagemeijer A, Judson I; EORTC Soft Tissue and Bone Sarcoma Group; Italian Sarcoma Group; Australasian GastroIntestinal Trials Group.

Eur J Cancer. 2006 May;42(8):1093-103. Epub 2006 Apr 18.

PMID:
16624552
11.

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.

Wardelmann E, Merkelbach-Bruse S, Pauls K, Thomas N, Schildhaus HU, Heinicke T, Speidel N, Pietsch T, Buettner R, Pink D, Reichardt P, Hohenberger P.

Clin Cancer Res. 2006 Mar 15;12(6):1743-9.

12.

Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala.

McLean SR, Gana-Weisz M, Hartzoulakis B, Frow R, Whelan J, Selwood D, Boshoff C.

Mol Cancer Ther. 2005 Dec;4(12):2008-15.

13.

Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour.

Grimpen F, Yip D, McArthur G, Waring P, Goldstein D, Loughrey M, Beshay V, Chong G.

Lancet Oncol. 2005 Sep;6(9):724-7. No abstract available.

PMID:
16129374
14.

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.

Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom AT, Goldstein D, Sciot R, Hogendoorn PC, Brown M, Bertulli R, Judson IR.

J Clin Oncol. 2005 Aug 20;23(24):5795-804.

PMID:
16110036
15.

Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.

Noma K, Naomoto Y, Gunduz M, Matsuoka J, Yamatsuji T, Shirakawa Y, Nobuhisa T, Okawa T, Takaoka M, Tomono Y, Hiroyuki O, Gunduz E, Tanaka N.

Oncol Rep. 2005 Sep;14(3):645-50.

PMID:
16077968
16.

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.

Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, Milanov ZV, Atteridge CE, Biggs WH 3rd, Edeen PT, Floyd M, Ford JM, Grotzfeld RM, Herrgard S, Insko DE, Mehta SA, Patel HK, Pao W, Sawyers CL, Varmus H, Zarrinkar PP, Lockhart DJ.

Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11011-6. Epub 2005 Jul 26.

17.

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.

Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP.

Clin Cancer Res. 2005 Jun 1;11(11):4182-90.

18.

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.

Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J, Heinrich MC.

J Clin Oncol. 2005 Aug 10;23(23):5357-64. Epub 2005 May 31. Review.

PMID:
15928335
19.

Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations.

Wardelmann E, Thomas N, Merkelbach-Bruse S, Pauls K, Speidel N, Büttner R, Bihl H, Leutner CC, Heinicke T, Hohenberger P.

Lancet Oncol. 2005 Apr;6(4):249-51. No abstract available.

PMID:
15811621
20.

KIT/Val654 Ala receptor detected in one imatinib-resistant GIST patient.

Tamborini E, Gabanti E, Lagonigro MS, Negri T, Pilotti S, Pierotti MA, Pricl S.

Cancer Res. 2005 Feb 1;65(3):1115; author reply 1115. No abstract available.

Supplemental Content

Support Center